Patents by Inventor Martin James Inglis Andrews

Martin James Inglis Andrews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
    Patent number: 10568867
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: February 25, 2020
    Assignee: GALAPAGOS NV
    Inventors: Steven Emiel Van der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20180221334
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: January 9, 2018
    Publication date: August 9, 2018
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVERT, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
    Patent number: 9895347
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: February 20, 2018
    Assignee: Galapagos NV
    Inventors: Steven Emiel Van Der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Cystic Fibrosis
    Publication number: 20160317493
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: May 2, 2016
    Publication date: November 3, 2016
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVERT, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
    Patent number: 9351955
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: May 31, 2016
    Assignee: Galapagos NV
    Inventors: Steven Emiel Van Der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20160022633
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: July 24, 2015
    Publication date: January 28, 2016
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVERT, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
    Patent number: 9133210
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: September 15, 2015
    Assignee: Galapagos NV
    Inventors: Steven Emiel Van Der Plas, Hans Kelgtermans, Sébastien Jean Jacques Cédric Dropsit Montovert, Sébastien Laurent Xavier Martina, Martin James Inglis Andrews
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 9006237
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: April 14, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS
    Publication number: 20150045327
    Abstract: The present invention discloses compounds according to Formula I: wherein R1 is as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment cystic fibrosis by administering a compound of the invention.
    Type: Application
    Filed: August 5, 2014
    Publication date: February 12, 2015
    Inventors: Steven Emiel VAN DER PLAS, Hans KELGTERMANS, Sébastien Jean Jacques Cédric DROPSIT MONTOVER, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS
  • Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases
    Publication number: 20120232075
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 13, 2012
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8178530
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 15, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus MacLeod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8173656
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 8, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8148369
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: April 3, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Giovanni Alessandro Tricarico, Grégory Louis Joseph Bar, Kim Louise Hirst, Olga Raquel Pinto Santos Oliveira Roussel, Juha Andrew Clase
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8138193
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: with Z, R1, R2, R8 and R9 as defined in the written description. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: March 20, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Grégory Louis Joseph Bar
  • Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8133895
    Abstract: Novel fused pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammation, rheumatoid arthritis and others.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: March 13, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Wolfgang Schmidt, Grégory Louis Joseph Bar
  • IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20120010206
    Abstract: Novel imidazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
    Type: Application
    Filed: May 25, 2011
    Publication date: January 12, 2012
    Inventors: Paul John EDWARDS, Sébastien Laurent Xavier MARTINA, Martin James Inglis ANDREWS, Grégory Louis Joseph BAR, Brigitte ALLART, Andrew BURRITT, Xueliang TAO, Friedrich Erich Karl KROLL
  • IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110218178
    Abstract: Novel imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, arthritis, inflammation, and others.
    Type: Application
    Filed: December 16, 2010
    Publication date: September 8, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Reginald Christophe Xavier Brys, Philip Huxley, Wolfgang Schmidt, Veronique Birault, Mark Stuart Chambers, Clifford John Harris, Angus Macleod, Kim Louise Hirst, Juha Andrew Clase, Gregory Bar
  • Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases
    Patent number: 8012983
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine and imidazo[1,2-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Grant
    Filed: May 6, 2009
    Date of Patent: September 6, 2011
    Assignee: Galapagos NV
    Inventors: Martin James Inglis Andrews, Mark Stuart Chambers, Hervé Van De Poël, Grégory Louis Joseph Bar
  • TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
    Publication number: 20110178067
    Abstract: Novel [1.2.4]triazolo[1,5-a]pyrazine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, and others.
    Type: Application
    Filed: January 9, 2011
    Publication date: July 21, 2011
    Inventors: Martin James Inglis Andrews, Paul Edwards, Mark Stuart Chambers, Wolfgang Schmidt, Juha Andrew Clase, Gregory Bar, Kim Louise Hirst, Angus Macleod
  • Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
    Patent number: 7977352
    Abstract: Novel triazolopyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, ECM degradation, joint degradation and/or inflammation, and others.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: July 12, 2011
    Assignee: Galapagos NV
    Inventors: Paul John Edwards, Wolfgang Schmidt, Veronique Birault, Friedrich Erich Karl Kroll, Andrew Burritt, Xueliang Tao, Martin James Inglis Andrews, Sébastien Laurent Xavier Martina